Skip to main content Skip to search Skip to main navigation
EMA: Pharmaceutical Quality System (PQS) Effectiveness Pilot Project

EMA: Pharmaceutical Quality System (PQS) Effectiveness Pilot Project

EMA launched a pilot under which EEA GMP inspectors will assess how sites demonstrate the effectiveness of their pharmaceutical quality system for risk-based change management, and whether the EEA GMP certificate could serve as the main evidence of this effectiveness.

The pilot will mainly include manufacturing sites producing sterile and / or non-sterile finished products and biological API sites.

The pilot explicitly uses PIC/S guidance PI 054-1 How to Evaluate and Demonstrate the Effectiveness of the Pharmaceutical Quality System with regard to Risk-based Change Management as its assessment basis and will run in selected GMP inspections during 2026-2027.

The GMDP Inspectors Working Group is inviting marketing authorisation holders and manufacturers to nominate their sites for onsite PQS effectiveness assessments by EEA GMP inspectors.


Source:

EMA: Pharmaceutical quality system (PQS) effectiveness pilot project

Meet the GMP Compliance Adviser

The GMP Compliance Adviser is the world's largest knowledge portal for quality management in the pharma business. 

The demo access is non-binding and ends automatically.

Test it now for free

You may also be interested in the following articles:

How do Components like Filling Needles and Laminarisators Affect First Air Integrity?

How do Components like Filling Needles and Laminarisators Affect First Air Integrity?

Here's the answer:
Read more
Smart Strategies for Handling Indirect Product Contact Components

Smart Strategies for Handling Indirect Product Contact Components

Aseptic filling processes: Handling indirect product contact parts in compliance with the revised Annex 1 of the EU GMP Guide.
Read more
Swissmedic: Implementation of New EU GMP Implementing Regulations for Veterinary Medicinal Products

Swissmedic: Implementation of New EU GMP Implementing Regulations for Veterinary Medicinal Products

The new EU Implementing Regulations on GMP requirements for veterinary medicinal products and active substances will not be automatically transposed into the Swiss Medicinal Products Licensing Ordinance (MPLO) on 16 July 2026. Swissmedic has confirmed that, although the structure of the new EU legislation has changed, the underlying GMP requirements remain largely unchanged.
Read more
EU: Annexes 4 and 5 no Longer Included in the EU GMP Guide

EU: Annexes 4 and 5 no Longer Included in the EU GMP Guide

Following the entry into application of Commission Implementing Regulations (EU) 2025/2091 and (EU) 2025/2154 on the principles and guidelines of Good Manufacturing Practice (GMP) for veterinary medicinal products and active substances for veterinary medicinal products on 16 July 2026, the European Commission removed Annexes 4 and 5 from the EU GMP Guide.
Read more
EMA: Revision of Annex 15 Delayed

EMA: Revision of Annex 15 Delayed

In February 2026, the EMA published a concept paper on the revision of Annex 15 "Qualification and Validation" of the EU GMP Guide (we reported previously). The Agency has now released a corrected version containing a significantly revised timetable.
Read more
EU: Updated Q&A on Safety Features for Human Medicinal Products

EU: Updated Q&A on Safety Features for Human Medicinal Products

The European Commission has published Version 22 of its Questions and Answers on Safety Features for Medicinal Products for Human Use.
Read more
Previous
Next